logo

Ardelyx, Inc (ARDX)



Trade ARDX now with
  Date
  Headline
12/4/2019 11:51:19 PM Ardelyx Announces Pricing Of Upsized Public Offering Of 20 Mln Shares At $6.25/Shr
12/3/2019 7:28:42 AM Ardelyx Announces Positive Topline Results From Phase 3 PHREEDOM Study Showing Tenapanor In CKD Patients On Dialysis
10/4/2019 6:15:36 AM New Drugs Approved In September
9/3/2019 8:06:59 AM Ardelyx Announces Positive Results From Pivotal Phase 3 AMPLIFY Study; Stock Surges
8/9/2019 8:09:44 AM Ardelyx Q2 Net Loss $25.5 Mln Or $0.41/shr Vs. Net Loss Of $22.3 Mln Or $0.42/shr Prior Year
5/7/2019 4:09:56 PM Ardelyx Q1 Loss/share $0.42 Vs. Loss $0.36 Year Ago
3/14/2019 5:02:38 PM Ardelyx Appoints Geoffrey Block To Its Board Of Directors
3/6/2019 4:10:20 PM Ardelyx Q4 Loss/share $0.45 Vs. Profit $0.21 Year Ago
2/7/2019 6:32:59 AM Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation Of Phase 2 Clinical Study Of Tenapanor
11/13/2018 8:42:52 AM Ardelyx Reports FDA Acceptance Of Filing Of NDA For Tenapanor For Treatment Of Patients With IBS-C
11/12/2018 9:31:47 AM Wedbush Is Cutting Ardelyx, Inc (ARDX) FY19 Estimate To -1.78 From -1.74
  
 
>